Loading
Life sciences · Journal article
International Journal of Pharmaceutical Research and Applications · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lipid nanoparticles (LNPs) have emerged as an advanced platform for drug and gene delivery, enabling the transition from conventional therapeutics to nucleic acid–based treatments. Solid lipid nanoparticles (SLNs), composed of biocompatible lipids, provide enhanced stability, reduced toxicity, and controlled drug release. The evolution from liposomes to modern systems such as nanostructured lipid carriers (NLCs) and ionizable LNPs has significantly improved the delivery of fragile biomolecules like mRNA and siRNA.Despite advantages, challenges such as immunogenicity, stability, and limited tissue targeting remain. Ongoing research into novel lipids and formulation strategies continues to expand LNP applications in gene therapy, cancer treatment, and personalized medicine.